Aberrant cytoplasmic sequestration has been reported as an alternative mechanism of p53 inactivation to mutation in neuroblastoma. We hypothesized that p53 localization and function in neuroblastoma is related to differentiation status. Eighty-two untreated and 24 paired pre and post-chemotherapy neuroblastomas were studied by immunocytochemistry for p53, p21 WAF1 , BAX, Bcl2 and Ki67. Predominantly nuclear p53 was detected in undifferentiated neuroblastoma, and both nuclear and cytoplasmic p53 in differentiating neuroblastoma. The nuclear p53 labeling index (LI) correlated with the Ki67 LI (r = 0.51, p < 0.001), and weakly with p21 WAF1 (r = 0.37), but not with BAX or Bcl2. There was a significant reduction in p53, p21 WAF1 and Ki67 LI after chemotherapy (p < 0.01), an increase in BAX (p < 0.05), but no change in Bcl2. p53 localization and function were examined in two p53 wild-type undifferentiated and 9-cis retinoic acid differentiated neuroblastoma cell lines. Using immunocytochemistry, immunofluorescence and cell fractionation, p53 was found to be predominantly nuclear in both undifferentiated and differentiated cells. Following irradiation, there was upregulation of p53, p21 WAF1 and MDM2, but less induced PARP and caspase 3 cleavage in differentiated cells, suggesting intact p53 transcriptional function, but resistance to apoptosis. p53 function in undifferentiated and differentiated cells was confirmed by upregulation of p21 WAF1 and MDM2 following Nutlin-3 treatment. In conclusion, p53 is predominantly nuclear and functional in neuroblastoma regardless of differentiation status.
developed a missense mutation at codon 135 in the cell line established from the same patient at relapse. 4 Despite being wild-type, p53 has been reported to accumulate in neuroblastoma, exhibiting enhanced stability. 5 The presence of accumulated p53 in neuroblastoma has been suggested to be due to the embryonic nature of these tumors, reflecting a failure of the precursor cells to mature. 5 Early studies reported cytoplasmic sequestration of wild-type p53 in undifferentiated neuroblastomas, where this phenotype was associated with a failure to G 1 arrest following DNA damage, and thus cytoplasmic sequestration was proposed as a non-mutational mechanism for p53 inactivation and accumulation in neuroblastoma. 6, 7 Several mechanisms for cytoplasmic sequestration have been proposed, most recently due to hyperubiquitylation of p53. 8 However, we and others have reported predominantly nuclear localization of p53 in neuroblastoma cell lines and an intact downstream transcriptional response after DNA damage. 9, 10 Eizenberg et al. previously reported that p53 plays a regulatory role in the differentiation and apoptosis of central nervous system associated cells, where p53 levels and subcellular localization were found to change during maturation. 11 In this study we hypothesized that p53 localization and function is dependent on the differentiation status of neuroblastoma and investigated this in neuroblastoma tumors and neuroblastoma cell lines undergoing retinoic acid induced differentiation.
MAteriALs And Methods
Tumors. Eighty-two untreated neuroblastomas or ganglioneuroblastomas were identified from the Northern Region Children's and Young Person's Malignant Disease Registry, and two mature ganglioneuromas. One formalin-fixed, paraffin-embedded block with the most undifferentiated tumor present, was selected from each case, together with some surrounding normal tissue, if possible, to provide an internal control. From five of these cases frozen tissue was also studied by immunocytochemistry, and in five cases tumors were also analyzed by Western blotting. Twenty-four pre-and post-induction chemotherapy stage 3 and 4 neuroblastomas from patients diagnosed between 1990 and 1999 were also studied. All patients had received standardized chemotherapy (seven courses of cisplatin based OPEC/OJEC 12 or more dose intensive rapid COJEC, or CADO/ VPCarbo 13 ). Surgery was undertaken around three weeks after the final course of chemotherapy if a bone marrow complete response, and at least a primary tumor partial response, had been obtained. Post-chemotherapy tumors were carefully reviewed to ensure there was adequate neuroblastoma remaining using the NB84 antibody to demarcate residual tumor.
International neuroblastoma pathology classification (INPC). All untreated tumors were reviewed by two European Neuroblastoma Study Group histopathologists [S.V and C.C] and classified according to the INPC and the Shimada system. 14 This involved classifying tumors as neuroblastoma (Schwannian stroma-poor) or ganglioneuroblastoma stroma-rich (>50% Schwannian stroma). The latter are subdivided into nodular or intermixed. If nodular, the stroma-poor nodule was classified along with other stroma-poor neuroblastomas into International Neuroblastoma Classification (INC) undifferentiated, if neuropil was absent, and poorly differentiated or differentiating, if it was present. Poorly differentiated and differentiating tumors were distinguished by the % of cells with ganglionic differentiation. The % of cells with convincing neuronal differentiation was also quantified separately as 0%, <5%, or >5%. The Mitosis Karyorrhexis Index (MKI), an index of mitotic and apoptotic cells, was recorded as low (<100/5000 cells per high power field), intermediate (100-200) or high (>200/5000). Calcification and the presence of anaplasia were also recorded. Tumors were classified as having unfavorable or favorable histology according to the Shimada and INPC systems of classification using previously published criteria including age, presence of Schwannian stroma, differentiation and MKI. 14 Cell lines and retinoid treatment. Two p53 wild-type neuroblastoma cell lines established from untreated neuroblastomas at diagnosis were used in this study, 15 MYCN amplified NBLW 16 and non-MYCN amplified NB69 17 were maintained in RPMI 1640 (Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum (Sigma), 100units/ml penicillin, and 100 mg/ml streptomycin (Sigma) in a 37°C, 5% CO 2 humidified incubator. 9-cis retinoic acid (RA) powder (Sigma) was dissolved in ethanol to 1mg/ml and diluted in cell culture medium prior to use to obtain final concentrations of 1 x 10 -6 M, with a maximum ethanol concentration of 0.1%. The culture medium was replaced every two days with fresh medium containing RA or control solvent. Cells were treated for a maximum of seven days. Cellular morphology in terms of neurite extension and length were captured using a Nikon COOLPIX 4500 camera attached to an Olympus LH50A inverted phase-contrast microscope. Neurite length was measured from the photomicrographs using NIH image analysis software, Image J, available at rsb.info.nih.gov/ij/.
Immunocytochemistry (ICC). Three micrometer sections were cut from formalin-fixed, paraffin-embedded cell cytoblocks and tumors, and placed on adhesive-coated (3-aminopropyltriethoxysilane) (Sigma) microscope slides. ICC was also performed on cells cultured on Labtek™ chamber glass slides (Nunc, Naperville, IL) treated with either RA or control solvent for seven days. ICC was performed using the streptavidin-biotin peroxidase technique (as previously described Ref. 9). Primary antibodies used were mouse monoclonal p53 DO-7 (amino acids 20-25) at 1:50, p53 Pab1801 (amino acids 46-55) at 1:40, Ki67 (MM1) 1:200, NB84 1:200, Bcl2 1:50 (all NovoCastra, Newcastle upon Tyne, UK), p53 DO-1 (amino acids 20-25) hybridoma supernatant 1:4, p21 WAF1 1:50 (Calbiochem, Cambridge, MA), and rabbit polyclonal BAX antibody 1:250 (Santa Cruz, Los Angeles, CA). Secondary antibodies used were rabbit anti-mouse biotinylated antibody 1:500 (Dako, Glostrup, Denmark) and swine anti-rabbit biotinylated antibody 1:1000 (Dako). Negative controls included incubations without primary antibodies and surrounding non-tumor tissue. Specificity controls for p53 included Western blotting in five cases and antigen-absorption controls in six cases. Antigen-absorption controls were performed using a blocking peptide of ten amino acids to the p53 DO-7 antibody (QETFSDLWKL) and a control unrelated peptide (glutathione S transferase) of 20 amino acids (TAGGWAAASDSRKGGEPAGY).
Tumor scoring. The Labeling Index (LI), % of immunostained cells, was determined by counting 1000 cells in the areas of densest immunostaining using an Olympus CX microscope at x 40 magnification. For BAX scoring, intensity was used as it produced diffuse cytoplasmic immunostaining of neuropil which made it difficult to determine which cell the staining originated from. This was graded as: 1, no staining; 2, mild; 3, moderate; and 4, intense staining. Cell fractionation. Cells were separated into nuclear and cytoplasmic fractions using the CelLytic™ Extraction Kit (Sigma). The samples were quantified and subjected to Western blot analysis as described below. To determine the integrity of the fractions, both control nuclear and cytoplasmic antibodies were included: TBP (TATA Binding Protein) (Abcam, Cambridge, UK) 1:1000 and porin (Invitrogen) 1:1000, respectively.
Irradiation induced DNA damage and Nutlin-3 treatment. The undifferentiated and RA differentiated cells were treated with 4Gy X-irradiation from a RS320 irradiation system (Gulmay Medical, Surrey, UK). Cells were harvested at 0, 2, 6 and 24 hours post irradiation for protein analysis. Nutlin-3 (Cayman Chemical, Ann Arbor, MI) was dissolved in DMSO (Sigma) to a 10mM stock solution and diluted in cell culture medium prior to use. The undifferentiated and RA differentiated cells were treated with 10 mM or 20 mM of Nutlin-3, or an equal volume of DMSO. Cells were harvested six hours after treatment for protein analysis.
Western blot analysis. Whole cells were lysed and Western blot analysis was performed using previously described methods. 9 Primary antibodies used were p53 DO-7 (Novocastra) 1:1000, MYCN NCMII100 1:10, Bcl2 (Novocastra) 1:100, PARP (Santa Cruz) 1:1000, cleaved caspase 3 (New England Biolabs, Beverly, MA) 1:1000, b-actin (Sigma) 1:500, MDM2 (Calbiochem) 1:100, and p21 WAF1 (Calbiochem) 1:100. Secondary goat anti-mouse/ rabbit HRP conjugated antibody (Dako) was used at 1:500. Protein detection was performed using enhanced chemiluminescence (GE Healthcare, Buckinghamshire, UK) (as previously described in ref. 9) . Protein levels were quantified by densitometry analysis using a FUJI-LAS-3000 system and analyzed using the AIDA analyzer program (Raytek, Sheffield, UK).
resuLts
Neuroblastoma tumors. Eighty-two untreated neuroblastoma and ganglioneuroblastoma tumors were studied, 7 (9%) stage 1, 11 (13%) stage 2, 9 (11%) stage 3, 51 (62%) stage 4 and 4 (5%) stage 4s tumors (International Neuroblastoma Staging System), 19 and two ganglioneuromas. From 24 of these cases tumor was also studied post chemotherapy. Since tumors were obtained between 1968 and 1999, during which time neuroblastoma treatment changed considerably, tumors were grouped according to year of diagnosis as follows: 1968-77, 1978-87, 1988-1999 (Table 1 ). In 1977 referral of neuroblastomas to Newcastle for multiple modality treatment commenced and in 1987 dose-intensive chemotherapy commenced. 20 In this study, stage has been classified as: stage 1, 2 and 4s (low-risk), stage 3 and infant stage 4 (intermediate-risk) and stage 4 over 1 year of age (high-risk) ( Table 1) . Infants with stage 4 disease have a better prognosis than older children. 21 Histopathological classification was attempted in 77 tumors; in five there was insufficient or inadequate material and for some categories e.g., MKI, only 65 could be classified (Table 1 ). There was only one case classified differently between the Shimada and International Neuroblastoma Pathology Classification (INPC) systems, so in subsequent analyses only the INPC system was used. NB84, a neuroblastoma marker was positive in 79/81 (98%) tumors. Nine cases of undifferentiated neuroblastoma were confirmed as neuroblastoma by a combination of raised urinary catecholamines, MYCN amplification and NB84 positivity. In the analyses poorly differentiated and differentiating tumors were combined, < 5% and > 5% neuronal differentiation were combined, and intermediate and high MKI tumors were combined. Since anaplasia was present in only three tumors this was excluded from further analysis.
p53 expression and localization. p53 expression detected by Western blotting was specific, and expressed at higher levels in a stage 4 poorly differentiated neuroblastoma than a stage 1, poorly differentiated neuroblastoma, two mature ganglioneuromas and a post-treatment adrenal neuroblastoma (Fig. 1A) . The presence of additional bands in the two mature ganglioneuromas are most likely to represent non-specific bands rather than p53b or p53g isoforms despite being of approximately the correct molecular weight (46 kd) and detectable using the p53DO-7 antibody which recognizes the N terminal. 22 This is because this blot was originally probed for MDM2 when a 98kd protein could not be identified, but several lower molecular weight bands including the additional bands in the two mature ganglioneuromas were present (data not shown). The same blot was then reprobed for p53 (Fig. 1A) . The p53b isoform has recently been reported in a p53 mutant neuroblastoma cell line. 23 The post treatment adrenal gland did not express p53 consistent with a previous study reporting that neuroblastomas overexpress p53 relative to bovine adrenal medulla. 5 Using three different p53 antibodies covering two separate N terminal epitopes, p53 was found to be predominantly nuclear in formalin fixed and frozen neuroblastoma (Figs. 1B, D and 2E ). p53 expression was heterogeneous within tumors and the percentage of cells with nuclear expression quantified using the LI. In cells showing increased differentiation towards ganglion cells (reduced nuclear to cytoplasmic ratio, increased neuropil, increased basophilic cytoplasm), some cytoplasmic p53 could be identified (Figs. 1E and 2B and E), particularly with the Pab1801 antibody. However,
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p53 Localization in Neuroblastoma Tumors and Cell Lines in some differentiating neuroblastoma cells, particularly those post chemotherapy, this cytoplasmic staining was also present in controls without primary antibody ( Fig. 2A and D) . Furthermore, compared with Bcl2, the p53 cytoplasmic immunostaining was much weaker (Fig. 2F) . Using antigen-absorption controls with a blocking peptide for the DO-7 epitope, all the nuclear and some cytoplasmic staining were abrogated (Figs. 1G and 2G ). Using an unrelated peptide, cytoplasmic p53 staining was abrogated and nuclear p53 staining was weaker, suggesting that the p53 antibody bound more strongly to nuclear p53 or the cytoplasmic staining was at least partly nonspecific (Figs. 1H and 2H ). The weak cytoplasmic p53 expression seen in the mature ganglioneuroma in Figure 2B is consistent with much lower levels of p53 expression by Western blotting compared with the other tumors in Figure 1A . In the subsequent analyses only nuclear p53 was scored.
Nuclear p53 accumulates in unfavorable neuroblastoma.
The labeling indices (LI) for all antibodies for the untreated neuroblastomas are shown in Table 2 . The median LI was chosen as a cut-off between high (positive) and low (negative) expression, except for BAX where ≥ 3 + (moderate expression) was used as the cut-off. p53 LIs detected by DO-7 and DO-1 antibodies were similar, but the Pab1801 LI was lower (Table 2 ). p53 expression detected by DO-7 strongly correlated with expression detected by the other two p53 antibodies (DO-7 v DO-1 r = 0.85, DO-7 v Pab1801 r = 0.74, DO-1 v Pab1801 r = 0.74, Spearman correlation p < 0.0001) (data not shown). Seventeen out of 82 tumors were biopsied from a metastatic site other than bone marrow (Table 1 ). There was no significant difference between p53 or p53 regulated protein expression in tumors biopsied from either the primary site or a non-bone marrow metastasis (data not shown). High p53 expression was associated with (Table 2 and Fig. 3A) , and undifferentiated tumors defined by both the % of cells with neuronal differentiation and the international neuroblastoma classification of differentiation (INC) ( Table 2 and Fig. 3B ). In contrast Bcl2 LI was higher in INC Group 2 (poorly differentiated and differentiating neuroblastoma) than Group 1 (undifferentiated neuroblastoma) (Fig. 3C) . High Ki67 expression, a proliferation marker, was associated with high p53 expression (Table 2 ) and the labeling indices correlated (r = 0.51, p <0.0001) (Fig. 3D) . p53 expression was associated with p21 WAF1 expression by Chi-squared analysis (Table 2) , although the labeling indices only weakly correlated (r = 0.37, p < 0.001 DO-1) (Fig. 3E) .
At the time of analysis, 36 patients whose untreated tumors were studied were alive and 39 patients had died from disease. The median overall survival (OS) was 44 months (range 0-395) and progression free survival (PFS) 26 months (range 0-395). Using univariate logrank analysis, age ≥ 12 months, stage risk group, high p53 expression with all three antibodies, neuroblastoma type, INPC unfavorable histology, 0% tumor cell differentiation, the absence of calcification and year of diagnosis were all adverse prognostic indicators for both PFS and OS (Fig. 3F and data not shown) . Stage risk groups and year of diagnosis were the most significant prognostic markers p < 0.0001 for both OS and PFS.
Multivariate forward and backward stepwise Cox regression analysis for OS and PFS was carried out, including variables found to be statistically significant on univariate analysis at ≤ 5%. As each variable was considered in the regression analysis of OS and PFS and then either added or removed, only stage (1, 2 and 4s-low and 3 and 4-high) and year of diagnosis remained significant. This was also the case when p53 LI was considered as a continuous variable (data not shown).
In the paired pre and post chemotherapy neuroblastomas there was a significant reduction in the p53 LI, as well as p21 WAF1 and Ki67, in tumors post-chemotherapy compared with untreated tumors (Suppl . Table 1A) , and a significant increase in the proportion of tumors immunostaining positive for BAX post-chemotherapy (Suppl . Table 1B ). There was no change in Bcl2 LI between pre and post-chemotherapy tumors (Suppl . Table 1A) .
Cell lines. Retinoic acid induced differentiation. To induce differentiation, NB69 non-MYCN amplified and NBLW MYCN amplified neuroblastoma cell lines were treated with 1mM RA and the onset of differentiation was monitored by neurite extension (Fig. 4A) . Additionally, using light microscopy,0 a decrease in proliferation was observed. Cellular differentiation was defined by the presence of neurites at least twice the length of the cell body. Three differentiation markers; neurofilament, synaptophysin and tyrosine hydroxylase were also used to confirm differentiation by 
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Western blot and immunofluorescence. Western analysis found that none of the tested differentiation markers were consistently upregulated despite obvious morphological differentiation, suggesting that there is a redistribution of differentiation markers rather than upregulation of expression (data not shown).
p53, Bcl2 and MYCN expression after differentiation. The protein levels of p53 and Bcl2 were examined in undifferentiated and RA differentiated NB69 and NBLW cells, and MYCN in MYCN amplified NBLW cells. Following differentiation, p53 levels decreased in NB69 cells (Fig. 4B(ii) ), but not in NBLW cells (Fig. 4B(i) ) (as previously reported, refs. 5 and 24) and supports the earlier observation of higher p53 expression by ICC in undifferentiated neuroblastoma (Table 2 and Fig. 3B ). MYCN levels in NBLW cells decreased following differentiation (Fig. 4B(i) ) consistent with previous reports in MYCN amplified cells. 25 Bcl2 levels increased after differentiation in both cell lines (Fig. 4B) , consistent with (previous reports, refs. 26-28) and the earlier observation of increased Bcl2 expression in poorly differentiated and differentiating neuroblastomas compared with undifferentiated tumors (Fig. 3C) .
p53 localization in undifferentiated and differentiated neuroblastoma cell lines. Both ICC and IF were used to immunolocalize p53 within cells. p53 was found to be predominantly nuclear in both undifferentiated and differentiated NB69 and NBLW cells using two different p53 antibodies (Fig. 5C, D and F) . The negative controls gave expected results. To confirm the results of ICC and IF, cell fractionation was performed (Fig. 6A ). This showed predominantly nuclear p53 in both undifferentiated and differentiated NB69 and NBLW cells, confirming the results of ICC and IF. In addition lower levels of nuclear p53 were observed in NB69 cells after retinoic acid induced differentiation (Fig. 6A(ii) ) consistent with the results shown in Figure 4B (ii) for this cell line.
p53 function in response to irradiation and Nutlin-3 treatment in undifferentiated and differentiated neuroblastoma cells. p53 transcriptional function was assessed in response to irradiation induced DNA damage using Western blotting to measure induction of p53 and p53 responsive genes encoding MDM2 and p21 WAF1 . After irradiation, p53 was stabilized in both undifferentiated and differentiated NB69 and NBLW cells by two hours and sustained until 24 hours (Fig. 6B) . Similarly, MDM2 and p21 WAF1 , the products of p53 responsive genes, were induced in both cell lines. Induction of MDM2 occurred maximally at six hours after irradiation, and induction of p21 WAF1 occurred by two hours and was sustained until 24 hours. A higher basal level of p21 WAF1 expression was observed in differentiated cells of both cell lines compared to undifferentiated control cells (Fig. 6B) , consistent with previous reports. 29 Induction of apoptosis was assessed by Western blotting to detect cleaved PARP and cleaved caspase 3 as early markers of apoptosis. 
Cleavage of PARP and caspase 3 was evident six hours post irradiation in both undifferentiated NBLW and NB69 cells, but there was minimal evidence of cleaved PARP or caspase 3 in differentiated cells (Fig. 6B) . This is consistent with previous reports showing resistance to cytotoxic agents after retinoic acid induced differentiation. 26, 28, 30 Nutlin-3 is a potent and selective small-molecule antagonist of the MDM2-p53 interaction, which results in stabilization of p53 and induced expression of p53 target genes in cells with wild-type functional p53. 31 To provide further evidence that p53 is functional in undifferentiated and differentiated NB69 and NBLW cells, cells were treated with Nutlin-3 or DMSO vehicle control for 6 hours. Induction of p53 and p53 target genes, p21 WAF1 and MDM2 was observed in both undifferentiated and differentiated cells after treatment with 10mM or 20mM of Nutlin-3 compared to cells treated with DMSO (Fig. 6C) , and further confirms that p53 is functional, and transcriptionally active after differentiation. Again, a higher basal level of p21 WAF1 expression was observed in differentiated cells of both cell lines compared to undifferentiated control cells (Fig. 6C) , consistent with the data in Figure 6B and also previous reports. 29 
discussion
The prognosis for children with high-risk neuroblastoma (stage 4 disease over one year of age, or localized or infant neuroblastoma with MYCN amplification) remains poor with <30% long term survival. Although p53 mutations have been found in a small proportion (~2%) of untreated neuroblastomas at diagnosis, p53 cellular localization and function in neuroblastoma are still controversial areas of research. We examined p53 localization and mediators of p53 function in a panel of 82 untreated neuroblastoma and ganglioneuroblastoma tumors which were a representative, unselected sample comprising 60% stage 4 disease and a median age at presentation of 26 months, consistent with previous large surveys. 32 In addition we examined p53 localization and mediators of its function in a subset of 24 paired pre and post chemotherapy neuroblastomas.
p53 immunostaining was found to be predominantly nuclear in both formalin-fixed and frozen neuroblastomas consistent with previous studies on formalin-fixed material, [33] [34] [35] [36] but not a single study of frozen neuroblastoma, in which predominantly cytoplasmic p53 was reported in undifferentiated neuroblastoma using the same p53 antibodies. 6 Using the median LI as a cut-off between high and low expression, the current study found high nuclear p53 expression to be associated with INPC undifferentiated neuroblastoma, and both nuclear and cytoplasmic p53 immunostaining was observed in differentiating neuroblastoma using all three antibodies, particularly Pab1801. Nuclear and some cytoplasmic staining was abrogated using a specific peptide antigen-absorption control, and the cytoplasmic, but not the nuclear staining, was also abrogated by an unrelated peptide control, suggesting that either the antibody binds more strongly to nuclear p53, or the cytoplasmic staining is at least partially non-specific. However, it is likely that some cytoplasmic 
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p53 does exist in neuroblastoma, as nuclear localization sequences for both p53 nuclear import and export exist, 37 a cytoplasmic anchor for p53 has been identified, Parc, 38 and a role for mitochondrial associated p53 in inducing apoptosis has been proposed. 39 In an immunohistochemical study of neuroblastoma tumors by Douc-Rasy et al., the subcellular distribution and staining intensity of p73, a member of the p53 family, varied with the amount of neuronal differentiation and there was a redistribution of p73 from the nucleus to the cytoplasm during neuroblastic differentiation. 40 Additionally, Eizenberg et al found that during maturation of primary oligodendrocytes and neurons, the subcellular localization of p53 changes from being predominantly in the nucleus during differentiation to predominantly cytoplasmic in fully mature cells p53. 11 Due to the structural and partial functional homology between p73 and p53, and the observations in primary oligodendrocytes and neurons, 11 it is possible there may be a redistribution of p53 following differentiation of neuroblastoma cells.
To further investigate this we examined p53 localization and function in a p53 wild-type MYCN amplified and a non-MYCN amplified cell line undergoing RA induced differentiation. To date no study has investigated the localization of p53 in neuroblastoma cell lines undergoing differentiation. We found p53 to be predominantly nuclear in both undifferentiated and RA differentiated cell lines and there was no redistribution following retinoic acid induced differentiation.
In contrast to some previous studies, 6,41 the evidence presented here suggests that p53 is predominantly nuclear in both neuroblastoma tumors and cell lines before and after differentiation, particularly as some cytoplasmic p53 staining observed in differentiating neuroblastoma tumors was non-specific. The observation of higher p53 expression in undifferentiated, Ki67 expressing tumors is consistent with results in NB69 cells showing higher levels of p53 in undifferentiated cells compared with differentiated cells.
To determine whether nuclear p53 is transcriptionally active in untreated neuroblastoma we measured expression of two proteins that p53 transcriptionally upregulates, p21 WAF1 and BAX, together with one it may transcriptionally repress, Bcl2. In this series of neuroblastomas p53 expression was found to correlate weakly with p21 WAF1 expression, but not Bcl2 or BAX. There is evidence to suggest that p53's transcriptional function is best assessed by MDM2 and p21 WAF1 upregulation, as induction of BAX is dependent on cell type. 2 However, evaluation of two different MDM2 antibodies on formalin-fixed, paraffin-embedded tumor samples proved unsatisfactory for ICC.
Comparing paired pre and post-chemotherapy neuroblastoma, we observed a reduction in nuclear p53, Ki67 and p21 WAF1 and an increase in BAX, suggesting selective killing of p53 expressing cells by chemotherapy. It is possible an increase in p53 and p21 WAF1 expression occurred initially after chemotherapy, as upregulation of p53, p21 WAF1 and MDM2 was detectable six hours after ex-vivo irradiation of one of the diagnostic, untreated paired tumors, 9 but a sustained increase in p53 and p53 regulated protein expression persisting until the time of surgical resection three weeks after the final course of chemotherapy would not be expected. It is interesting that BAX expression increased in post-chemotherapy tumors, which may be a delayed effect of p53 activation. In the ex-vivo tumor described above, BAX expression was unchanged six hours after irradiation. 9 Increased BAX expression, reduced Ki67, increased apoptotic index and unchanged p53 levels have been reported in locally advanced colorectal cancers studied before and two weeks after radiotherapy and chemotherapy. 42 In paired non-metastatic rectal tumors investigated pre and post-radiochemotherapy, there was no change in p53 or BAX levels, but a reduction in p21 WAF1 and Ki67, and patients with a decrease in p21 WAF1 or an increase in Ki67 expression had improved survival. 43 In the current study all except one of the paired pre and post chemotherapy cases responded to chemotherapy, with at least a partial response at the primary site, consistent with a functioning p53 pathway at diagnosis.
We also investigated p53 function after differentiation measured by transcriptional activity and induction of apoptosis in neuroblastoma cell lines. We showed that p53 is functional after DNA damage in undifferentiated and differentiated NB69 and NBLW cells, as evident by p53 stabilization and the induction of p53 responsive genes encoding MDM2, and p21 WAF1 . Additionally, treatment of undifferentiated and differentiated NB69 and NBLW cells with Nutlin-3, a specific p53-MDM2 antagonist, showed stabilization of p53 and induced expression of p21 WAF1 and MDM2, providing confirmatory evidence of intact p53 function after differentiation. Consistent with previous studies we observed a reduction in irradiation induced apoptosis in differentiated cells. 28, 30 In contrast to the study by Ronca et al who proposed that retinoic acid confers resistance to chemotherapeutic agents by modulating nuclear import of p53, 30 the present study shows that after irradiation induced DNA damage in differentiated neuroblastoma cell lines, there is nuclear translocation of p53, and the induction of p53 responsive genes encoding MDM2 and p21 WAF1 . This is despite a lower level of apoptosis, suggesting the latter may be p53 independent in differentiated neuroblastoma, possibly by involving effects on apoptotic pathways downstream of p53.
This study is the first to investigate p53 localization in cell lines undergoing RA induced differentiation, and also in such a large series of neuroblastomas, which included both formalin-fixed and frozen tumors. The results of the present study show that aberrant cytoplasmic localization is uncommon in undifferentiated and differentiated neuroblastoma, and is unlikely to be an important mechanism of p53 inactivation in this tumor. The presence of transcriptionally active nuclear p53 in differentiating neuroblastoma cell lines suggests that mechanisms other than inactivation of the p53 pathway, makes these cells more resistant to apoptosis. 
